KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Return on Sales (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Return on Sales for 13 consecutive years, with 0.1% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 10.0% year-over-year to 0.1%, compared with a TTM value of 0.05% through Dec 2025, up 5.0%, and an annual FY2025 reading of 0.05%, up 5.0% over the prior year.
  • Return on Sales was 0.1% for Q4 2025 at Travere Therapeutics, up from 0.0% in the prior quarter.
  • Across five years, Return on Sales topped out at 6.47% in Q3 2023 and bottomed at 1.14% in Q1 2021.
  • Average Return on Sales over 5 years is 0.36%, with a median of 0.0% recorded in 2025.
  • The sharpest move saw Return on Sales soared 596bps in 2023, then plummeted -647bps in 2024.
  • Year by year, Return on Sales stood at 0.56% in 2021, then rose by 20bps to 0.68% in 2022, then tumbled by -105bps to 0.03% in 2023, then skyrocketed by 100bps to 0.0% in 2024, then surged by 181434bps to 0.1% in 2025.
  • Business Quant data shows Return on Sales for TVTX at 0.1% in Q4 2025, 0.0% in Q3 2025, and 0.0% in Q2 2025.